Slide 1: Covering letter to stock exchanges
October 23, 2024 To, The Secretary, The Secretary, Listing Department, Listing Department, National Stock Exchange of India Limited BSE Limited Exchange Plaza, 5th Floor, Phiroze Jeejeeboy Towers C/1 G Block, Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai - 400 051 Mumbai- 400 001 (Scrip Cod
Slide 2: Thyrocare Earnings Presentation Q2 FY25
Thyrocare Earnings Presentation Q2 FY25
Slide 3: Safe harbour statement
Safe harbour statement Statements in this presentation describing the Company’s performance may be “forward looking statements” within the meaning of applicable security laws and regulations. Actual results may differ materially from those directly or indirectly expressed, inferred or implied. Impor
Slide 4: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 02
Slide 5: Delivered 20% YoY revenue growth in Q2 FY25
Delivered 20% YoY revenue growth in Q2 FY25 while maintaining highest quality standards Acquisition of Clinical 32 Labs Diagnostic Business of (28 NABL Accredited) “Vimta Labs” Financial Parameters Operational Parameters Quality Parameters ► Consolidated Revenue for Active 8,400+ Samples 96% Q2 FY25
Slide 6: 96% of our sample load is processed in NABL labs
96% of our sample load is processed in NABL labs 32* 28 29 28 17 8 Q2FY23 Q2FY24 Q2FY25 No of labs NABL labs ► 2 New Lab added in Q2FY25. NABL Labs (28) ► West : Navi Mumbai, Mumbai (Kurla), Pune, Raipur, Ahmedabad, Nagpur, Mumbai (Kandivali), Goa ► East : Kolkata, Bhubaneswar, Guwahati, Patna, Ranc
Slide 7: Expansion in North India through acquisition of Polo Labs
Expansion in North India through acquisition of Polo Labs ► In Sept 2024, we hosted a Meet & Greet event for our Polo Lab clients, welcoming them to the Thyrocare family. ► Thyrocare has completed the acquisition of Polo Labs on July 29, 2024. ► Polo Labs is a pathology diagnostic company based out
Slide 8: Acquisition of Clinical Diagnostic Business of Vimta Labs
Acquisition of Clinical Diagnostic Business of Vimta Labs ► This acquisition strengthens our footprint in southern India, enabling us to serve a broader customer base with high-quality, affordable diagnostics. ► By aligning our operational efficiency, quality focus, and cost structure, we create syn
Slide 9: NABL and CAP certified lab signifying top quality standards
NABL and CAP certified lab signifying top quality standards The recognition of CAP and NABL is a testament to the highest standards and stringent benchmarks for quality, accuracy and safety. Recognition by CAP 3 additional labs covered under NABL scope ► 3 more labs - Kandivali, Goa and Mohali, are
Slide 10: Strengthening our relationships with doctors and channel partners
Strengthening our relationships with doctors and channel partners Advisory Board Meeting with doctors Strengthening our Channel partners ► Hosted our 3rd Advisory Board Meeting in August 2024 with ► Hosted channel partner meet in Pune to reward and strengthen our a panel of esteemed doctors to gain
Slide 11: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 09
Slide 12: Quarter health check - Financial Performance Q2 FY25
Quarter health check - Financial Performance Q2 FY25 YoY TTL Consolidated YoY Pathology Revenue +20% Revenue* +20% YoY Radiology YoY Normalized Revenue** +21% EBITDA +23% YoY Reported EBITDA +28% Normalized EBITDA% 29% * Pathology business excluding materials & others ** Radiology includes pulse hit
Slide 13: Half year health check - Financial Performance H1 FY25
Half year health check - Financial Performance H1 FY25 YoY TTL Consolidated YoY Pathology Revenue +18% Revenue* +18% YoY Radiology YoY Normalized Revenue** +18% EBITDA +17% YoY Reported EBITDA +25% Normalized EBITDA% 29% * Pathology business excluding materials & others ** Radiology includes pulse h
Slide 14: Strong and consistent growth outlined by key metrics
Strong and consistent growth outlined by key metrics Tests performed (Mn) Patients (Mn) Active Franchisees (#) +15% +9% +13% 44.0 4.4 8,447 7,451 38.2 4.0 4.0 6,479 36.2 Q2FY23 Q2FY24 Q2FY25 Q2FY23 Q2FY24 Q2FY25 Q2FY23 Q2FY24 Q2FY25 Revenue per Test (INR) Revenue per Patient (INR) Tests per Patient
Slide 15: 20% YoY revenue growth in overall business; 23% YoY growth in Normalized EBITDA
20% YoY revenue growth in overall business ; 23% YoY growth in Normalized EBITDA Consolidated Revenue (INR Cr) Normalized EBITDA (INR Cr) +20% +23% 177.4 50.7 154.2 156.9 44.7 148.0 41.2 134.7 36.7 34.7 157.2 50.7 131.5 138.8 138.6 43.5 118.6 40.3 35.8 33.6 0.9 1.0 0.9 1.3 0.0 11.7 11.9 12.8 13.0 14
Slide 16: Franchise revenue grew by 14% YoY; Partnerships grew by 40% YoY
Franchise revenue grew by 14% YoY ; Partnerships (excluding API) grew by 40% YoY Pathology Revenue (Rs Cr) YoY% Pathology Workload (Lakhs) YoY% 98.2 46.1 +14% 43.6 +9% 88.2 42.2 86.4 40.0 83.2 36.5 75.7 47.1 48.9 +33% 36.8 41.7 18.7 +29% 35.5 33.9 15.8 15.9 +40% 14.5 13.3 24.2 28.4 28.7 24.0 11.1 +5
Slide 17: Strong organic growth with a potential to expand further with M&A
Strong organic growth with a potential to expand further with M&A Consolidated Revenue Particulars (INR Cr) Q2FY25 Organic revenue (A) 176.1 Inorganic revenue (B) 1.3 Consolidated revenue (A+B) 177.4 Comparison of organic and consolidated revenue of Q2FY25 with Q2FY24 The strong organic growth refle
Slide 18: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 16
Slide 19: Income statement - TTL Standalone: Jump in PAT by 45% YoY
Income statement - TTL Standalone : Jump in PAT by 45% YoY Quarter Half Year INR crore Q2FY25 Q2FY24 YoY H1FY25 H1FY24 YoY Pathology revenue grew by 20% YoY, Revenue from operations 163.1 136.3 20% 306.7 259.9 18% Franchise grew by 14%; Partnerships Cost of materials consumed/sold (47.8) (41.3) (90.
Slide 20: Income statement - NHL Standalone
Income statement - NHL Standalone Quarter Half Year INR crore Q2FY25 Q2FY24 YoY H1FY25 H1FY24 YoY NHL Revenue grew 17% YoY on Revenue from operations 12.6 10.7 17% 24.0 21.8 10% account of increase in FDG sales and Cost of materials consumed/sold (3.1) (2.3) (5.5) (4.5) better realization per scan.
Slide 21: Income statement - TTL Consolidated: Jump in PAT by 29% YoY
Income statement - TTL Consolidated : Jump in PAT by 29% YoY Quarter Half Year INR crore Q2FY25 Q2FY24 YoY H1FY25 H1FY24 YoY Revenue from operations include Revenue from operations 177.4 148.0 20% 334.3 282.9 18% Pulse Hitech, Think Health and Polo Cost of materials consumed/sold (51.0) (43.6) (96.4
Slide 22: Balance Sheet - TTL Consolidated
Balance Sheet - TTL Consolidated INR crore Sep24 Mar24 INR crore Sep24 Mar24 Non-current assets Equity Property, plant & equipment 156.1 168.4 Equity share capital 53.0 53.0 Capital work-in-progress 0.6 2.6 Other equity 435.2 473.8 Goodwill 105.2 104.0 Non-controlling interests 0.5 0.9 Other intangi
Slide 23: Cash Flow Statement - TTL Consolidated
Cash Flow Statement - TTL Consolidated : Operating Cash flow increased by 28% Half Year INR crore H1FY25 H1FY24 Operating activities : Incremental cash A. Cash flow from operating activities generated from the operating activities Profit before tax 71.0 52.7 by INR 19.6 Cr, i.e, 28% over H1FY24. Non
Slide 24: Agenda
Agenda Latest updates 01 Latest updates Performance highlights 02 Performance highlights Financial performance 03 Financial performance Going forward strategy 04 Going forward strategy 22
Slide 25: Vision & Mission
Vision & Mission Global in our reach, excellence in our experience To ensure everyone has access to quality & affordable diagnostics 23
Slide 26: Going forward - Key pillars of growth
Going forward - Key pillars of growth Public & private International Franchise partnerships expansion ► Going deeper into India ► Focus on TB and Exploring to take our with focused test menu infectious disease along B2B model to emerging ► Strengthening our with large screening markets to deliver ex
Slide 27: Our strategy remains to be a B2B service provider with an affordable value driven model
Our strategy remains to be a B2B service provider with an affordable value driven model based on scale efficiencies Franchise Partnership + B2G ► Mom & Pop collection centres ► Online diagnostic aggregators ► Local labs ► Healthcare platforms 66% ► Nursing homes & hospitals ► Employee wellness platf
Slide 28: Thank You
Q Thyrocare Tests you can trust For Any queries, please reach out to investor_relations@thyrocare.com Thank You Disclaimer This presentation is for information purposes only and it contains general background information about the Company’s activities. The Company assumes no responsibility to public